CBD Archives - Green Market Report

Sean HockingSean HockingApril 24, 2019


Not long ago, scientists had no idea that a major body system existed. While studying the way cannabis interacts with the body in the 1900s, scientists found that the compound THC was binding to receptors in a system they had never noticed before.

They began studying this system and found that it was extremely complex and had a large impact on the way the body functions. They named it the endocannabinoid system after the plant that led to its discovery.

Since then scientists have learned more and more about the way this incredible system affects our bodies. From regulating pain receptors to stimulating serotonin levels, the endocannabinoid system has an impact on our lives every day. While the endocannabinoid system works great on its own, CBD and other cannabis compounds can interact with system receptors to provide an all-natural healing effect.



What is the Endocannabinoid System?

The endocannabinoid system is comprised of a series of receptors, enzymes and endogenous cannabinoids. The system’s main function within the body is to help maintain a healthy internal balance – what many scientists refer to as “homeostasis.” It does this by using receptors to interact with various internal and external compounds to regulate our various systems and boost our overall health.

There are two main types of receptors which are present throughout the body – the CB1 receptor and the CB2 receptor. The CB1 receptor is the most prominent and is found in the brain, central nervous system, reproductive system, cardiovascular system, and the liver, among others. The CB2 receptor is more scarce and is found mostly in peripheral systems. The CB2 receptor, however, still plays a very important role in the endocannabinoid system.

Our bodies naturally produce compounds called “endogenous cannabinoids” that interact with the endocannabinoid system. The main two compounds that scientists have found are anandamide and 2-AG. Both of these are produced within our body and interact with CB1 and CB2 receptors to make sure our body is working the way it is supposed to be.

The endocannabinoid system has been found to help regulate a variety of different systems and can combat a variety of ailments. For example, according to this 2018 article on cannabinoid receptors and the endocannabinoid system by S. Zou and U. Kumar, “the endocannabinoid system [is] largely involved in various aspects of central neural activities and disorders, including appetite, learning and memory, anxiety, depression, schizophrenia, stroke, multiple sclerosis, neurodegeneration, epilepsy, and addiction. The CB1 [receptor] is also involved in physiological and pathological conditions in the PNS (peripheral nervous system) and peripheral tissues, including pain, energy metabolism, cardiovascular and reproductive functions, inflammation, glaucoma, cancer, and liver and musculoskeletal disorders.”

Copy and paste this link in your browser to take you to the study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877694/.

Learning how to tap into the endocannabinoid system could help researchers find ways to treat a plethora of health problems. While the endogenous cannabinoids our bodies make do their part in keeping us strong and healthy, sometimes they need a little help. That’s where external cannabinoids come into play.

What Are Phytocannabinoids and Why Are They Important?

In general, scientists are aware of two types of cannabinoids. Endogenous cannabinoids and phytocannabinoids. Endogenous cannabinoids include anandamide and 2-AG and are produced by our bodies to interact with CB1 and CB2 receptors. Phytocannabinoids, on the other hand, are produced by cannabis plants.

When these external cannabinoids are ingested, they interact with CB1 and CB2 receptors in similar ways as endogenous cannabinoids. By doing this, phytocannabinoids can actually boost the endocannabinoid system and help it function differently or even more effectively than it can on its own.

Scientists believe there are up to 100 different cannabinoids produced by cannabis plants, but only five are worth mentioning in this article. The most important phytocannabinoids are THC, CBD, CBG, CBC and CBN.



THC is arguably the most well-known cannabinoid. THC is produced by marijuana and is the culprit behind the psychoactive effects most marijuana users experience. Because of its high concentrations of THC, marijuana is illegal in most parts of the United States.

CBD, on the other hand, is produced in the highest concentrations by hemp plants. Although hemp is a strain of cannabis, it produces little to no THC. Instead, it makes high quantities of CBD, CBG, CBC and CBN. These four cannabinoids don’t cause any psychoactive effects and actually have little to no negative side effects. Instead, when they interact with CB1 and CB2 receptors, they can actually boost the endocannabinoid system’s effectiveness to help moderate pain, regulate mental disorders such as anxiety and depression, improve sleeplessness, increase appetite, reduce nausea and promote muscle and bone growth.

Each of these cannabinoids produces a slightly different effect. For example, CBN is known for its ability to help reduce the side effects of those who suffer from sleep disorders. CBC is popular for its ability to regulate pain and reduce inflammation. In addition to acting as an anti-inflammatory and aiding sleep, CBG promotes healthy bone growth. Because of their individual effects, many hemp farmers have learned how to grow strains of plants that produce even more of the desired cannabinoid.

The “king” of cannabinoids, however, is undoubtedly CBD. CBD provides a long list of health benefits. For example, CBD can help regulate the immune system, is an anti-oxidant and anti-bacterial agent, helps sooth the side effects of anxiety and depression, reduces nausea and soothes severe and chronic muscle and joint pain, among other things.


Where Can I Learn More?

Over the years many scientific articles have been published about CBD and the endocannabinoid system as a whole. Many of them are free to the public. A short list of some relevant articles will be included below.


  • Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry1(7), 1333–1349. http://doi.org/10.4155/fmc.09.93
  • Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., … McCormick, P. J. (2012). Cannabinoid Receptors CB1 and CB2Form Functional Heteromers in Brain. The Journal of Biological Chemistry287(25), 20851–20865. http://doi.org/10.1074/jbc.M111.335273
  • Zou, S., & Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International journal of molecular sciences19(3), 833. doi:10.3390/ijms19030833
  • Lu, H. C., & Mackie, K. (2015). An Introduction to the Endogenous Cannabinoid System. Biological psychiatry79(7), 516–525. doi:10.1016/j.biopsych.2015.07.028
  • Fine, P. G., & Rosenfeld, M. J. (2013). The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides medical journal4(4), e0022. doi:10.5041/RMMJ.10129

StaffStaffApril 19, 2019


In case you haven’t heard, CBD is on the rise. Cannabis-based products like CBD oil are quickly becoming both viable medical alternatives and pleasurable indulgences for people around the world, in markets that are starting to truly take off. It’s a time of great innovation and fast growth for the extract-inclined, even despite legal setbacks and gray areas in certain markets and countries that have yet to be resolved. People believe CBD can truly improve their lives, so it’s unlikely that the product’s massive market expansion will stop anytime soon.

There’s just one issue, though: the same market growth that attracts investors and companies can be confusing and illegible to the average consumer, especially if they’re not familiar with the wide landscape of available CBD products beforehand. Sure, the market has lots of choices, and constant competition will only push companies to improve and iterate upon their products until they can capture the hearts, minds and market share of a consistent customer base. But that understandably could confuse many who just want to know which CBD products will get them the most bang for their buck, where they should buy them, and why. Where should one find best quality cannabis seeds? Is a CBD oil product that’s good for anxiety also good for migraines or PTSD? Even simple questions like this could confuse newcomers.

That’s why we’ve put together this list of five must-have CBD products currently on the market today! In Ontario, weed online can be found. These products will get you well on your way to find it! If you’re a total beginner to the CBD space, then all five will provide a solid starting point for you to build a knowledge of what works for you and what doesn’t.

On the other hand, if you’re an old hand and you already know what you want in terms of CBD products, then you should take a look at this list anyways — if you are missing any of the items on this list, you’re slacking! It could be time to play catch-up. Either way, no matter who you are and where you are in your CBD journey, check out the products below to get our take on five of the most essential CBD products out there.

Extra-Strength Relieving Spray

I bet ten years ago, you never thought there’d be CBD-infused body sprays, huh? Science is crazy.

But now that we’re living in the future, this body spray is one of the coolest, and most effective, products out there. It’s a fast-acting body spray that you can use on achy joints, inflamed skin, sore muscles, or whatever other problems your body is giving you when you wake up in the morning! It’s made of totally organic essential oils and other natural plant extracts, like peppermint, juniper, and CBD, designed specifically to reduce pain and inflammation. One to two sprays should be all it takes to work out any muscle kinks or swollen joints. In addition, this spray comes in a small bottle, so it’s perfect to take on the go when you need pain relief that you can take with you in your purse or gym bag.

CBD+ Vaporizer

Beautiful graphic design. A product that would look at home on a millennial bookshelf with vinyl records and streetwear baseball caps. A smart, disposable design that is eye-catching without being ostentatious.

This disposable, beautiful CBD+ vaporizer is all that and more. It’s filled with pure CBD oil as well as other essential oils to give you the treatment you need in a 500mg formation. Whether you want to treat arthritis, anxiety, or you just need a quick and convenient way to de-stress with a quick CBD intake, this vaporizer is one of the best options out there. No matter what part of your body aches, this vaporizer is one of the most stylish ways to put yourself on the path to recovery we’ve seen on the CBD market.

Full-Spectrum CBD Oil

Maybe you want to keep things simple. Rather than spend your disposable income on fancy new CBD products, you’d like to spend that money on finer ingredients, and you’re just looking for the highest quality oil you can find. If that’s the case, don’t worry; we’ve got you covered as well with this CBD oil.

This all-natural oil, made totally additive-free and preservative-free, is 100% organic, made from non-GMO plants right in Colorado, USA. Not only is it a natural and environmentally ethical option; it’s also a high-grade product. 5mL of this oil contains approximately 240mg of CBD extract. This oil would be a good choice for anybody with chronic pain, anxiety, or any other medical condition that CBD can treat.

CBD Capsules

Another high-quality and conscientiously-made CBD product, capsules are a great option for those who’d like to ingest their CBD rather than vaping it or using it in a rubbing formulation.

The main function of CBD capsules is to treat stress and anxiety; they’ll increase your awareness and boost your brain function so that you can stop stressing and start living more in the moment. At 15mg per capsule, and manufactured with CBD from Hudson Valley, NY, these cool caps will satisfy anybody who’s looking for a literal chill pill.

CBD Oil Tincture with Turmeric

Finally, the last item on our list is a tincture. There are many tincture-style formulations that have come onto the market recently, touting CBD as a cure-all for your bodily aches and pains, but this one is the real deal. This tincture is extracted from hemp and combined with turmeric for maximum effectiveness; you’ll likely need just a few drops to start feeling CBD’s healing effect. This is a good choice for those who want to keep form factor low and not spend a lot of money on a vaporizer or another accessory.


Hopefully, this list has given you a couple of ideas on where to start or how to supplement your existing collection of CBS oils, tinctures, balms and accessories. It should help you find where to purchase the best quality cannabis seeds. Results for CBD usage often vary from person-to-person, but what we can guarantee is that every single one of these products is well-designed and created for you to get the most out of your CBD treatment. The ability to buy weed online Quebec has never been easier.

Author Bio

Jessica Smith has been closely studying the cannabis industry trends from quite some time. Intrigued by the booming growth of this sector, she takes an interest in penning down her views providing quality insight on current marijuana trends, particularly medical cannabis.


Caroline CahillCaroline CahillApril 5, 2019


The CBD industry has been moving full steam ahead in 2019, bolstered by the 2018 Farm Bill and advancements on the federal level to ensure cannabis banking services, but that progress hasn’t been enough for some financial services institutions to continue working with the industry.

On March 14, 2019, Elavon, a payment processing subsidiary of U.S. Bank, notified its hemp and CBD clients that it had recategorized hemp and cannabidiol-based merchants as a prohibited business type and that accounts for such merchants would be closed within 45 days.  

“After several months supporting this merchant segment, it has become clear that the pace of an evolving Federal and State regulatory framework makes it extremely difficult to validate the qualifications required to operate within this industry,” said Elavon in an email to its hemp and CBD clients.

As an Elavon partner, FINCANN, a cannabis banking financial network, received Elavon’s notice and began sourcing solutions for its clients at once.

“We immediately reviewed remaining available options and within 24 hours had viable USA-based excellent alternatives available,” said Nathaniel Gurien, founder and CEO of FINCANN. “Since Elavon is not terminating their existing portfolio of CBD merchants until May 15, some merchants opted to immediately apply to one of our alternatives, others decided to wait and see until at least mid-April.”

Elavon isn’t the only merchant services provider rethinking its hemp and CBD clients. On March 19, Cannovia, a maker of CBD-infused products, was notified by Stripe that its account would be terminated. Having just launched its online storefront on March 14, Cannovia attempted to appeal Stripe’s decision but was denied.

“Prior to the notification of the merchant services cancellation, we were not fully aware of the limitations of the banking industry to support the needs of the CBD industry,” said Brian Baum, the CEO of Cannovia.

With both Stripe and Elavon out of the picture, Cannovia soon learned that finding a merchant services provider on its own wouldn’t be easy.

According to Baum, “What became clear was that the options were limited and any banks willing to consider supporting the industry were beginning to utilize the services of intermediaries such as FINCANN to assist them in managing the sheer volume of entities looking for merchant services solutions.”

Linking up with FINCANN to secure a new merchant services provider allowed Cannovia to remain operational and avoid any major interruptions.

Meanwhile, both financial institutions and industry stakeholders continue to keep an eye on the SAFE Banking Act, which would provide certain protections for depository institutions that work with cannabis-related businesses as well as the businesses themselves. The House Committee on Financial Services is currently drafting a report on the act to present to the House of Representatives. If the full House approves the bill, the Senate will vote on it.   

“If the SAFE Banking Act overcomes its estimated 40% likelihood of passing the Senate, it will only encourage banks currently contemplating ‘dipping their feet into the water’ to ‘take the plunge,’” Gurien said. Once financial institutions take the plunge, legal cannabis-related businesses will be able to bank just like any other legal business.


Debra BorchardtDebra BorchardtFebruary 26, 2019


Zynerba Pharmaceuticals, Inc. (ZYNE) stock popped over 8% in early trading to lately trade at $5.45 after the company announced that it had received a patent covering the company’s CBD gel.

The company said in a statement, “The U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company’s cannabidiol (CBD) product candidate, ZYN002 Transdermal CBD gel.”

The company said that the issuance of this patent comes as enrollment progresses in CONNECT-FX, a pivotal, multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ZYN002 in three through 17-year old FXS patients with a full mutation of the FMR1 gene. The primary endpoint is the change from baseline to the end of the treatment period in the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS) Social Avoidance subscale.

Zynerba said in a statement that clinical investigative sites are enrolling patients in the United States, Australia, and New Zealand. Patients who have completed the double-blind phase are now enrolling into the 12-month open-label phase. The company expects to report top-line data in the second half of 2019.

This follows the company recent news that the International Intellectual Property Organization issued a patent on a Zynerba’s CBD-based drug to treat osteoarthritis. Zynerba had conducted a study that showed that CBD could be an effective treatment for patients suffering from osteoarthrits. The administration of a CBD transdermal gel showed an improvement in pain. This patent will allow Zynerba to tap into a large osteoarthritis market occupied primarily by opioids

2018 wasn’t especially kind to Zynerba. It’s failed ZYN001 drug was a huge setback. Then the company’s stock offering was met with dismay by investors. Many felt the company had enough cash to see it through additional R&D and that it didn’t need to add more shares to the mix. Zynerba planned to use the net proceeds of the offering to support the clinical development of ZYN002


Debra BorchardtDebra BorchardtFebruary 25, 2019


SOL Global Investments Corp. (CSE: SOL) (OTCQB: SOLCF)  is forming a new international hemp-focused subsidiary, Heavenly Rx Ltd. Its initial focus will be on hemp cultivation, processing and the manufacturing of a diverse range of traditional CBD products including oils, tinctures, balms, and vape-ready products. The company said it plans on holding a controlling ownership interest in various industry-leading assets in the hemp/CBD and THC-free cannabinoid wellness space.

One of the first strategic assets will be its investment in Knoxville, Tennessee-based Blühen Botanicals LLC. Heavenly Rx is investing $30.6 million in Blühen, which will allow Blühen to expand its research and engineering teams as well as focus on the development and expansion of its retail operations. According to the statement, Blühen is an industry leading and technologically advanced hemp biomass processing and extraction company that will be GMP and EUGMP certified with farming and distribution partners across the southeastern United States.

Blühen also produces its own proprietary blend of wellness boutique products such as full spectrum hemp extract tinctures, capsules, creams, 100% THC-free hemp isolate, pet treats, pet care products, and oils. Blühen employs expert entomologists, plant pathologists, agronomists, chemists, and engineers on the 30-person team. Blühen intends to open its flagship retail location in Knoxville, Tennessee in May 2019 and plans to open a second retail location in Fort Lauderdale, Florida later this year.

“Heavenly Rx directly supports SOL Global’s continued hemp and CBD strategy in the U.S. and international markets and will serve as a critical launch pad for our hemp-related investment initiatives as hemp and related cannabinoid regulations continue to become more liberalized around the world,” said Brady Cobb, CEO of SOL Global. “SOL Global’s executive team has been at the very forefront of regulatory reform both in the United States and internationally, and we couldn’t be more excited to continue to build upon and execute our already robust long-term strategy for the global hemp/CBD industry.”

Additionally, Heavenly Rx intends to include several proprietary brands across numerous consumer product group verticals such as cosmetics and beauty products, bath and body products, infused foods (subject to governmental approvals and/or compliance) and a number of pet-related products.

“We are launching Heavenly Rx with the aim of acquiring a portfolio of battle-tested and proven hemp/CBD companies while also acquiring certain unique brands for which we believe CBD and hemp-infused products could drastically change their growth,” added SOL’s chief investment officer Andy DeFrancesco. “We are more bullish than ever about the future of the hemp and CBD industries globally, and Heavenly Rx will without a doubt be the vertically integrated leader in the space.”


The binding terms of the LOI are as follows:

  • Heavenly Rx will acquire 50.1% of the membership interests of Blühen.
  • The Board of Directors of Blühen will consist of seven (7) individuals, three (3) of which will be nominated by Heavenly Rx, three (3) of which will be nominated by Blühen, and one (1) of which shall be an independent director to be mutually agreed upon.
  • Joe Fox, co-founder, and CEO of Blühen Botanicals, will become a member of the executive team of Heavenly Rx.

“Heavenly Rx’s investment enables us to exponentially scale our existing high-throughput capabilities while maintaining our commitment to providing the highest quality, pharmaceutical grade products on the market,” added Fox. “We have the largest network of expert farmers in the state of Tennessee who are growing hemp organically, and now, we’re empowered to scale our existing facilities faster, expand our farming network wider, and implement the highest international regulatory standards across the board.”

Debra BorchardtDebra BorchardtFebruary 20, 2019


A letter to the (Food & Drug Administration) FDA Commissioner Scott Gottlieb was penned by a group of politicians requesting guidance with regards to CBD (cannabidiol). The letter referred to New York City’s ban on food products containing CBD and enforcement actions happening in the states of Maine and Ohio.

Representative Chellie Pingree posted the letter on her Twitter feed. It acknowledged that the FDA had posted a response with regards to CBD following the passage of the 2018 Farm Bill. The letter also noted that there is a “tremendous amount of confusion among product manufacturers, hemp farmers and consumers.”

The letter said, “We are calling on the FDA to swiftly provide guidance on lawful pathways for food products with CBD.” The group asked that answers to the following questions be provided by Friday, February 22.

When will FDA provide guidance on lawful pathways for food products containing hemp-derived CBDin interstate commerce? For example, the GRAS Notification program seems as though it is one such pathway.

When will FDA hold a public meeting on the regulation of food products containing hemp-derived CBD in interstate commerce?

New York City’s Health Department has confused food producers and restaurants as well. The group initially banned all CBD food products, but then reversed course last week and delayed the ban until July 1. The information was sent out in an email to restaurant owners.

The NYC Hospitality Alliance said it has requested the DOH to provide guidance but has received no answers to its requests. “This aggressive enforcement is another example of New York City’s regulatory approach: issue fines first, and educate last. Issuing a violation for using CBD in food and drink is especially ironic to happen when New York is seriously considering legalizing marijuana.  Enough is enough.  The city must stop finding ways to fine our city’s small businesses.”

One manufacturer of CBD edible products said he was operating “business as usual” apparently unconcerned about the confusion created by the FDA.

Debra BorchardtDebra BorchardtFebruary 4, 2019


LB Equity has raised $50 million for a portfolio titled LB Equity Emerging Growth Fund, which will be concentrating its investments in cannabis companies that are involved in beauty, health, and wellness. The company’s first investment is with the platform Standard Dose, which is dedicated to selling hemp-based CBD products as well as educating consumers on these new products. The company did not announce how much of an investment it made into Standard Dose.

The retail platform will provide content to educate consumers on the emerging CBD market, plus current industry research and information about CBD products. This information will include dosage and regulatory updates.

The market has been exploding with CBD products since the 2018 Farm Bill was passed legalizing hemp and products made from hemp-derived CBD. The problem is that not all hemp CBD is created equally and there is quite a bit of inferior product on the market. Standard Dose is starting with 37 distinct beauty and lifestyle products that it has vetted and tested.

The company’s ingestible products include vape pens, tinctures, olive oil, honey, and beverages. Consumers should be aware though that the FDA must approve of any foods containing hemp-derived CBD. In a statement issued in December, the FDA said, “Congress explicitly preserved the agency’s current authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act.” The FDA went on to add, “The FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce.”

“Our goal at Standard Dose is to facilitate an honest conversation about CBD and to help consumers gain clarity of an industry that, until now, has been confusing and unregulated,” said Anthony Saniger, Founder and CEO of Standard Dose. “We take the time to vet all of our products and share information so that consumers can choose CBD products with confidence. With the very recent legalization of CBD, we know that interest in the industry and its products will skyrocket.”

LB Equity is led by Jay Lucas, a former partner at Bain & Company, Karen Ballou, a highly experienced beauty industry professional (Redken and Elizabeth Arden) and Jim Morrison, who served as President of L’Oreal U.S. for nearly 10 years. The extended team consists of strategy and investment professionals along with an advisory group of veteran industry executives across core value creation disciplines.  Prior to Standard Dose and the latest Fund, LBE has completed investments in ten additional beauty and personal care brands, including MD Complete, Marula Pure Oil, Immunocologie and Blamtastic among others.

“LBE is targeting the massive opportunity available at the intersection of the rapidly growing cannabis industry and the many emerging brands within the skincare, beauty and related personal care sectors,” said Jay Lucas, Managing Partner of LB Equity. “With experienced executives from both the finance and beauty industries, LBE is perfectly positioned to leverage the transformational impact that these newly legalized cannabis-based products will have on the beauty industry.”

Debra BorchardtDebra BorchardtJanuary 24, 2019


On February 3, the 53rd Super Bowl in Atlanta Georgia will decide the league champion of football for the 2018 NFL season. If you are in attendance at the Super Bowl, you will see CBD coffee ads in the stadium, but if you are watching the game from home you will be not be exposed to any cannabis related advertising.

New York-based Acreage Holdings, Inc. (CSE: ACRG.U) wanted to run an advocacy ad during the game. The ad featured three medical marijuana patients saying how the product had helped them. It made no health claims for their own products and it didn’t promote the purchase of the company’s products.

CBS which is airing the game sent an email to the company saying, “CBS will not be accepting any ads for medical marijuana at this time.” The ad would have cost approximately $5 million.

Acreage currently has the largest footprint of any cannabis company in the country with operations/licenses in 19 states. “It’s a public service announcement really more than it is an advertisement,” said Harris Damashek, Acreage’s chief marketing officer.

Football fans at the stadium will, however, see advertisements for Baristas Coffee Company, Inc. (OTCPK: BCCI) White Coffee and the new Baristas EnrichaRoast CBD Coffee. The White Coffee can be purchased through Amazon (www.trywhitecoffee.com) and the company’s new EnrichaRoast CBD Coffee (www.baristas.tv) which uses a proprietary technology introducing CBD to the beans after they are roasted can be purchased on the company’s website. 

The company said that the ads will run throughout the day in and around the stadium before, during, and after the game, and will include a special offer to send a message to Maroon 5. The spots will be seen on numerous digital displays including mobile devices allowing fans to connect via special Portals.

Baristas said that the CBD ads are only available due to Canna Broadcast Medias’ (OTCPK: CBMJ) geofencing platform which will deliver ads in and around the stadium. Canna Broadcast Media specializes in getting mainstream media cleared promoting the cannabis sector including network TV, radio, and digital ads targeting those who wish to take advantage of the incredible investment opportunities that exist in the cannabis sector.

“Having Baristas White Coffee and our new EnrichaRoast CBD coffee ads at the Super Bowl will give us tremendous exposure,” said Barry Henthorn Barista CEO. “We are thankful to the NFL, ReelTime Media, and Canna Broadcast Media for making this possible. Baristas is growing its market awareness and expanding its product offerings.”

Marijuana Super Bowl History

This isn’t the first time cannabis tried to insert itself into Super Bowl week. In 2014, the Marijuana Policy Project put up a series of billboards highlighting the safety of marijuana and challenged the NFL’s punishment of pot smoking vs. the approval of alcohol. Smart Approaches to Marijuana, the anti-marijuana group went on the defense with their own billboards, which sparked a billboard battle.


Debra BorchardtDebra BorchardtJanuary 23, 2019


Eaze just released its 2018 State of Cannabis report giving insight into the buying habits of cannabis consumers. Eaze is a Calfornia-based cannabis delivery software company with buying history from 450,000 cannabis shoppers who have used Eaze for its delivery software service along with 4,000 survey respondents.


Some of the key findings included the breakout year for CBD (cannabidiol) products and the increase in the number of women who have become cannabis consumers. The report called CBD the “darling” of 2018 after learning that CBD consumers nearly doubled in 2018 from 2.6% to 4.8%. Part of this could be attributed to the tsunami of CBD products hitting the market and the general acceptance of the product as being mostly legal. The 2018 Farm Bill legalized CBD derived from hemp. Baby boomers are driving the increased sales of CBD products with 8.4%  of that business coming from that age group.

Women, in particular, are drawn to making CBD purchases. The Eaze report said that “Their preferred products appear to be more ‘beginner’ friendly.” The CBD-only customers reported a variety of effects from taking the product. 61% reported relaxation, while 41% reported anxiety and stress relief, while 40% reported pain relief.


In 2015, women accounted for 25% of the cannabis market and that number has jumped to 38% in 2018. “Over the past year, the total number of women customers grew 92%,” said the report. It also suggested that at this rate, women could end up equaling men by the year 2022 for consumption.

Women were most likely to purchase edibles, drops, and topicals, while men tended to buy the traditional flower and concentrates.  Gummies and the biggest edibles seller followed by bites, chocolate bars, cookies, and mints, respectively. Women also tend to consume cannabis more for personal care and sleep, while men use it for at-home entertainment and sports or exercise.


The report also determined that cannabis consumers tended to give up other things once they began to make regular cannabis purchases. Millenials reduced alcohol consumption and the Gen Z folks either quit tobacco smoking entirely or at least cut it down. All demographics said they reduced their use of over-the-counter pain relievers and prescription pain medicines. Over the counter drug purchases fell by 71% and prescription painkillers fell by 35%.

It seems by consuming cannabis, people are focusing more on the benefits of wellness. Bad habits like alcohol and cigarettes drop as consumers look to cannabis to feel better and contribute to an overall wellness behavior.





About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 5 hours

RT : The rock stars of will be at the Green Market Summit in Chicago. You don’t want to miss this if you are in the…

@GreenMarketRpt – 9 hours

$APHA After the Drama, Where Is ⁦@aphriaUSA⁩ Headed Now?

@GreenMarketRpt – 1 day

RT : Saka is the perfect thing to look forward to after a long Monday! Have good week everyone!!

Back to Top

You have Successfully Subscribed!